Nemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Rhea-AI Summary
Nemaura Medical (NASDAQ: NMRD) announced CEO Dr. Faz Chowdhury will present at the MicroCap Rodeo Windy City Roundup 2022 Conference, taking place from October 12-13, 2022 at the Swissotel Chicago. His presentation is scheduled for 1:00 pm CT on October 12. Dr. Chowdhury will also hold one-on-one meetings with investors registered for the event. Nemaura specializes in non-invasive glucose monitoring technology, including products like sugarBEAT and proBEAT, addressing the growing market for diabetes management.
Positive
- None.
Negative
- None.
News Market Reaction – NMRD
In the trading session that priced this news, NMRD gained 2.19%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Loughborough, England, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference. The conference is being held on October 12 – 13, 2022 at the Swissotel Chicago.
Presentation Date: October 12, 2022
Time: 1:00 pm CT
Dr. Chowdhury will be available for one-on-one meetings with investors who are registered to attend the conference. To schedule a meeting, please email angie.wright@issuerdirect.com
To register for the conference, click here: https://microcaprodeo.com/signup
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
